BioMed Research International / 2014 / Article / Tab 3

Research Article

Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature

Table 3

Other characteristics of the tumors: in this table we present prevalences and values referring to chi-square test.

UBC1st MBC2nd MBC1st SBC2nd SBC

Grading
 G17.16% (35/489)7.69% (3/39)7.5% (3/40)12.5% (2/16)18.75% (3/16)0.480
 G267.48% (330/489)41.03% (16/39)55% (22/40)81.25% (13/16)68.75% (11/16)<0.05
 G325.36% (124/489)51.28% (20/39)37.5% (15/40)6.25% (1/16)12.5% (2/16)<0.05
ER positivity 73.3% (387/528)51.28% (20/39)67.5% (27/40)75% (12/16)81.25% (13/16)<0.05
PR positivity 68.94% (364/528)43.59% (17/39)60% (24/40)75% (12/16)75% (12/16)<0.05
HER-2/Neu positivity8.9% (47/528)7.69% (3/39)12.5% (5/40)6.25% (1/16)6.25% (1/16)0.912
Mib-1/Ki-67 (%)
 1 to 2034.98% (85/243)57.14% (4/7)32% (8/25)57.14% (4/7)60% (3/5)0.376
 20 to 3018.11% (44/243)0% (0/7)12% (3/25)0% (0/7)0% (0/5)0.331
 >3046.91% (114/243)42.86% (3/7)56% (14/25)42.86% (3/7)40% (2/5)0.911
Multifocality26.7% (141/528)5.13% (2/39)27.5% (11/40)50% (8/16)18.75% (3/16)<0.05
Extended in situ component22.16% (117/528)17.95% (7/39)32.5% (13/40)25% (4/16)0% (0/16)0.110
Peritumoral vascular invasion6.82% (36/528)5.13% (2/39)7.5% (3/40)6.25% (1/16)0% (0/16)0.850
Comedo-like necrosis8.9% (47/528)2.56% (1/39)12.5% (5/40)6.25% (1/16)6.25% (1/16)0.581
Lymph node isolated tumor cells3.6% (19/528)0% (0/39)0% (0/40)0% (0/16)0% (0/16)0.390
Lymph node extracapsular invasion2.27% (12/528)0% (0/39)0% (0/40)12.5% (2/16)0% (0/16)<0.05